Abstract: Copolymers of 2-acryloylamido-2-methylpropanesulfonic acid (AMPS) and acrylic acid (AA), as well as the corresponding homopolymers PAMPS and PAA, were studied in vitro on human pool plasma for their anticoagulant activity. The values of the haemostatic parameters -prothrombin time, activated partial thromboplastin time and thrombin time -depend on the composition and the concentration of the (co)polymers. Reptilase time remains unchanged on adding the (co)polymers. A broad concentration range from 16 µg/ml to 3 mg/ml was studied. The copolymers possess anticoagulant activity, which is higher at higher content of AMPS units. It was found that, at certain concentrations, the haemostatic parameters of PAMPS are close to that of heparin. PAA has the lowest anticoagulant activity.
Introduction
Blood clotting is a kind of protective reaction, which proceeds under the action of lowor high-molecular-weight substances. Thrombus formation occurs by polymerisation of the soluble fibrinogen under the action of the main catalyst of this processthrombin. Under the action of thrombin, fibrinogen turns to a fibrin monomer, which transforms to insoluble fibrin polymer as a result of polymerisation according to the following scheme: Heparin is a natural mucopolysaccharide, preventing thrombus formation. Its anticoagulant activity is attributed mainly to the presence of sulfate, sulfamide, and carboxylic groups and their conformation and arrangement along the chain. Heparin forms a complex with antithrombin ІІІ (the natural inhibitor of thrombin). The obtained complex promotes the inhibitory action of antithrombin ІІІ to thrombin. The structure of the pentasaccharide (1), which is responsible for the formation of this complex, is known [1] . The development of haemocompatible materials is one of the most challenging problems in biomaterials science. The polymers, from which intravenous catheters, dialysis membranes or cardiovascular devices might be prepared, have to satisfy the following requirements: to adsorb infinitesimal quantities of plasma lipoproteins, not to activate the contact factors of blood clotting, and not to provoke platelet adhesion and aggregation. It is also desirable that they play an active role in the reactions of lysis of the forming thrombus or that they activate the fibrinolytic system of the blood. Different approaches have been used for the modification of the surfaces of such devices with the aim to improve their haemocompatibility. The most frequently applied method is binding of heparin onto a polymer surface [2, 3] .
Studies of the interactions between immobilised heparin and two main plasma proteins (serum albumin and fibrinogen) and proteins, which are formed in blood after activation of the coagulation system (thrombin) or the anticoagulation system (fibrinolysis) have shown that heparin forms stable complexes with fibrinogen and thrombin [4] . The immobilised heparin forms considerably weaker complexes with fibrinolysin and does not form any complex with albumin. The binding strength of the immobilised heparin with proteins decreases in the order: fibrinogen ≈ thrombin > fibrinolysin ≈ albumin. A similar behaviour has been observed when studying heparin solutions. Attempts for synthesising of heparin structure analogues have been conducted. Semi-synthetic heparinoids based on chitosan sulfate [5, 6] or alginate sulfate [7] have been prepared.
Synthetic polymers and copolymers with heparin-like activity might find application as stabilizers for blood and blood plasma in laboratory practice, as well as for coating blood-contacting devices (catheters, dialysis membranes, blood vessel grafts). The advantages of such polymer materials are the facile preparation, low cost and stability to enzymatic degradation. Certain synthetic polyanions exhibiting anticoagulant activity are known. They are methacrylic copolymers, bearing sulfate, sulfamide, and carboxylic groups [8] . Derivatives of poly(cis-1,4-isoprene), poly(trans-1,4-isoprene) and poly(3,4-isoprene) have been prepared by the addition of chlorosulfonyl isocyanate [9] . The anticoagulant activity of these products depends on the content and the ratio of the ionisable functional groups.
Poly(2-acryloylamido-2-methylpropanesulfonic acid) (PAMPS) is a strong polyacid. PAMPS solutions (0.025 g/dl) inhibit complement activation and increase the receptivity of xenografts in test animals [10] . AMPS copolymerises with acrylic acid (AA) under the action of redox-initiator systems in good yields [11, 12] . Carboxylic and sulfo groups in different ratios are present in the obtained copolymers.
The present work reports a study on the anticoagulant activity of PAMPS and PAA, and of the copolymers based on AMPS and AA, denoted as P(AMPS n -co-AA n' ), where n and n' are the mole fractions of AMPS and AA units, respectively. In order to evaluate the effect of copolymer composition on their anticoagulant activity, the following copolymers were synthesised, purified and characterised -P(AMPS 0.1 -co-AA 0.9 ), P(AMPS 0.2 -co-AA 0.8 ), P(AMPS 0.5 -co-AA 0.5 ), P(AMPS 0.8 -co-AA 0.2 ), and P(AMPS 0.9 -co-AA 0.1 ). The measured values of the haemostatic parameters prothrombin time, activated partial thromboplastin time and thrombin time for human pool plasma were compared with those determined in the presence of heparin.
Results and discussion
In our previous study [12] , copolymers P(AMPS n -co-AA n' ) were obtained. It is known that PAMPS forms a complex with bovine serum albumin and the binding constant with the protein is very close or nearly identical to that of heparin [13] . It was of interest to evaluate the anticoagulant activity of the copolymers P(AMPS n -co-AA n' ) (2) and to compare it with the effect of PAMPS (3) and PAA (4) Copolymer composition was determined using two independent methods: elemental analysis (sulfur content) and 13 C NMR spectroscopy. In Fig. 1 , the 13 C NMR spectrum of P(AMPS 0.8 -co-AA 0.2 ) is shown. The mole fraction of AMPS units in the copolymer was determined by the ratio between the chemical shifts for C=O of AA units (around 181 ppm) and for C=O of AMPS units (around 178 ppm) according to literature data [11] . The copolymer composition determined by 13 C NMR spectroscopy was in very good agreement with the data obtained by elemental analysis.
The molecular-weight characteristics of the copolymers were determined using size exclusion chromatography (SEC). The number-average molecular weights (M n ) of P(AMPS 0.1 -co-AA 0.9 ), P(AMPS 0.2 -co-AA 0.8 ) and P(AMPS 0.8 -co-AA 0.2 ) were in the range 53·10 3 -60·10 3 , and those of P(AMPS 0.5 -co-AA 0.5 ) and P(AMPS 0.9 -co-AA 0.1 ) were higher than 315·10 3 .
Anticoagulant activity of the (co)polymers
The anticoagulant activity of the (co)polymers was studied in vitro using human pool plasma and it was evaluated from the obtained data for prothrombin time (PT), activated partial thromboplastin time (APTT) and thrombin time (TT). The values of these haemostatic parameters were calculated according to the following equations:
where PT c , APTT c and TT c are the values at a given sample concentration, and PT 0 , APTT 0 and TT 0 are those of the control assays in the absence of (co)polymers. 
PT assay
Prothrombin time (PT) is the time for coagulation of platelet-poor citrate plasma after the addition of tissue thromboplastin (factor ІІІ) at optimal content of calcium ions. The coagulation proceeds by the 'extrinsic coagulation pathway'. Heparin prolongs PT by inhibiting the coagulation enzymes, including thrombin and factor Xa.
It was found that the prolongation of РТ depends considerably on the composition of the copolymers P(AMPS n -co-AA n' ) at a concentration of 1.6 mg/ml (Fig. 2) . As seen from Fig. 2 , the effect of PAA on PT is insignificant and the value is close to that of the control assay. A similar behaviour was found for copolymers with mole fractions of AMPS units lower than 0.5. Enriching the copolymers in AMPS units leads to an increase of PT. PT is from 3 to 8 times higher for the copolymers P(AMPS 0.8 -co-AA 0.2 ) and P(AMPS 0.9 -co-AA 0.1 ) in comparison with P(AMPS n -co-AA n' ) where n ≤ n'. In the case of PAMPS homopolymer, PT is equal to the value determined in the presence of heparin (R PT = 18).
The dependence of R PT on the (co)polymer concentration in the range from 10 to 40 µg/ml is shown in Fig. 3 . As seen, in this concentration range the composition of the copolymers does not influence considerably the R PT value. The value increases on increasing the (co)polymer concentration. This latter tendency is the same when higher concentrations of the copolymers (up to 3.0 mg/ml) are applied (Fig. 4) . 
APTT(LT) and APTT(kaolin) assay
The activated partial thromboplastin time (APTT) is the time for coagulation of platelet-poor citrate plasma after adding partial thromboplastin (cefalin), in the presence of calcium ions and of a contact activator (e.g., kaolin) [19] . It is used for evaluating the 'intrinsic coagulation pathway'. These parameters follow the changes in hyper-and hypocoagulation in the presence of anticoagulants (heparin or substances with heparin-like activity).
The dependence of R APTT(LT) on the concentration of the (co)polymers is presented in Fig. 5 . Similarly to R PT , R APTT(LT) values increase on increasing the concentration of (co)polymers. In contrast to R PT , at concentrations in the range from 16 to 40 µg/ml the composition of the copolymers influence the R APTT(LT) values significantly. A considerable increase of R APTT(LT) was observed on increasing the mole fraction of AMPS units. For example, at a concentration of 40 µg/ml the R APTT(LT) value for P(AMPS 0.9 -co-AA 0.1 ) is 3 times higher than that for P(AMPS 0.2 -co-AA 0.8 ). 
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The dependence of R APTT(kaolin) on the concentration of the (co)polymers is similar to that of R APTT(LT) (Fig. 6) . The values of R APTT(kaolin) are considerably higher in the case of copolymers with higher content of AMPS units. At a concentration of 40 µg/ml, the R APTT(kaolin) value for P(AMPS 0.9 -co-AA 0.1 ) is 3.6 times higher than that for P(AMPS 0.2 - 

TT assay
Thrombin time (TT) is the time for coagulation of platelet-poor citrate plasma after adding a standard quantity of thrombin and an optimal quantity of calcium ions. This parameter measures the clotting time of the last step of the coagulation cascade, which is the conversion of fibrinogen into fibrin by thrombin. Thrombin cleaves fibrinogen-releasing fibrinopeptide A and B and converting fibrinogen into fibrin clot. It is known that heparin requires a plasma cofactor, antithrombin ІІІ (АТ ІІІ), for its anticoagulant activity [14] . АТ ІІІ is the natural inhibitor of thrombin. The inhibition proceeds by covalent binding of thrombin with АТ ІІІ. Heparin catalyses the inhibiting activity of AT by binding to it, thus converting AT ІІІ from a slow, progressive thrombin inhibitor to a very rapid inhibitor.
The changes in R TT as a result of adding the (co)polymers to the human pool plasma are presented in Fig. 7 . Similarly to R APTT , R TT depends on the composition and concentration of the copolymers. The values of R TT increase considerably on increasing the mole fraction of AMPS units in the copolymer. At a concentration of 40 µg/ml, the R TT value for P(AMPS 0.9 -co-AA 0.1 ) was 3.6 times higher than that for P(AMPS 0.2 -co-AA 0.8 ), similarly to R APTT . As seen from data presented in Fig. 7 , the highest value of this parameter was reached in the presence of PAMPS.
At higher concentrations of (co)polymers (1.6 mg/ml), a considerable prolongation of TT was observed. While TT of the control assay was 17 s, TT of the (co)polymers at this concentration was above 999 s. Therefore, in this case the (co)polymer composition did not influence significantly the TT value and fibrin did not form even after 999 s. 
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In order to clarify if the prolongation of TT is due only to the presence of the (co)polymers or to fibrinogen inactivation or other factors, the change of reptilase time (RT) in the presence of the (co)polymers was followed. In contrast to TT, RT is not prolonged in the presence of heparin and substances with heparin-like activity, since the plasma inhibitors (AT) of thrombin do not influence reptilase. The performed studies showed that in the presence of P(AMPS n -co-AA n' ) copolymers, PAMPS, or PAA, RT remained constant (16 -17 s) and was equal to that of the control assay. Therefore, TT was prolonged, and RT remained constant in the presence of P(AMPS-co-AA), PAMPS, and PAA. This proves that like heparin the studied (co)polymers exhibit anticoagulant activity. It might be assumed that, similarly to the proposed pathways of interaction of heparin with antithrombin III (AT) and thrombin (T) [15] , the anticoagulant effect of the investigated polyanions might follow one of the mechanisms shown in Scheme 1 -binding of AT (1) or T (2), or simultaneous binding of AT and T (3). In case (1), the polyanion first binds AT and then, the formed complex polyanion/AT, accelerates AT-T interaction. In the second case the polyanion first binds T, and then the formed complex polyanion/T accelerates the interaction of T with AT (2). A simultaneous binding of T and AT with the polyanion shown in case (3) is also possible.
From the performed in vitro studies on human pool plasma it was found that P(AMPS-co-AA) copolymers, PAMPS, and PAA exhibit anticoagulant activity depending on the composition and concentration of the (co)polymers. It was shown that increasing the mole fraction of AMPS units in P(AMPS n -co-AA n' ) resulted in enhanced anticoagulant activity.
Previously, we have shown that P(AMPS n -co-AA n' ) and PAMPS formed polyelectrolyte complexes with natural polycations [12, 16] . It might be assumed that, by complex formation of some of the studied (co)polymers, there is a possibility not only to prevent the haemostatic activity of synthetic or natural polycations, but also to prepare antithrombogenic materials. The possibility to use copolymers with high content of AMPS units for the modification of polymer surfaces in order to improve their haemocompatibility is currently being studied and will be reported further.
(1) Polyanion + AT → Polyanion/AT + T → AT-T + Polyanion 
Experimental part
Materials
The commercial monomers 2-acryloylamido-2-methylpropanesulfonic acid (AMPS) and acrylic acid (AA) were purchased from Fluka. AA was distilled prior to use under reduced pressure in the presence of hydroquinone. All reagents used for the preparation of the (co)polymers were of analytical grade of purity.
PAA was prepared by polymerisation of 25% solution of monomer at 60°C under nitrogen initiated with α,α'-azoisobutyronitrile in toluene ([M] = 4.6 mol/l, [I] = 0.002 mol/l). The degree of conversion was 96%. PAMPS was prepared via radical polymerisation as described previously [16] . The polymerisation was carried out at 25°С for 30 h, using the redox-initiator system: Fe(NH 4 ) 2 (SO 4 ) 2 (0.05 g/l), Na 2 SO 3 (2.2 g/l), and (NH 4 ) 2 S 2 O 8 (2.2 g/l). Yield: 95%.
The copolymers P(AMPS n -co-AA n' ) were obtained according to a procedure described previously [11, 12] . As an example, P(AMPS 0.9 -co-AA 0.1 ) was synthesised by dissolving 2.6 g AA (1.8 mol/l), 7.5 g AMPS (1.8 mol/l), and 3.2 ml of 10 M NaOH (1.6 mol/l) in water to a total volume of 20 ml. The solution was purged with nitrogen for 20 min, then the components of redox-initiator system, (NH 4 ) 2 S 2 O 8 (0.0332 g) and K 2 S 2 O 5 (0.0647 g), were added. The reaction mixture was stirred for 3 h at 20°C. The copolymer was isolated by precipitation into a large excess of acetone, dried under reduced pressure at 40°C, and purified by dialysis against distilled water. The conversion was 90% with respect to the total monomer feed.
Human pool plasma was obtained from clinically healthy volunteers. The reagents for determination of the haemostatic parameters (STA Neoplastin ® Plus, STA Thrombin, STA APTT LT, STA APTT Kaolin, STA Reptilase and STA Antithrombin III) were purchased from Roche Diagnostics (Germany). The accuracy and the reproducibility of the results were controlled using STA PreciClot Plus I (Normal) and STA PreciClot Plus II (Pathological). Heparin with an activity of 5000 IU/ml (Braun Melsungen AG) was used.
Methods for (co)polymer characterisation
The molecular-weight characteristics (M n , M v , M w , M w / M n ) of the copolymers were determined by size-exclusion chromatography (SEC) on a Waters apparatus equipped with a set of 3 Shodex OH pak (SB 806M) columns, differential refractometer and viscometer detector. The eluent was 0.5 M LiNO 3 with 6·10 -3 M NaN 3 at a flow rate of 0.75 ml/min at 40°C. Pullulan (PSL, MW 22.8·10 3 -788·10 3 ) and poly-(oxyethylene)s (Waters, MW 10.8·10 3 -690·10 3 ) were used as standards for calibration.
Intrinsic viscosity was measured with an Ubbelohde viscometer at 25 ± 0.1°С. The viscometric-average molecular weight (M v ) of PAA determined in 2 N NaOH was 4.3·10 4 as calculated using the equation [η] = 1.05·10 -3 · M v 0.54 [17] . M v of PAMPS (9.8·10 5 ) was determined in 5 N NaCl and was calculated from the equation [η] = 2.11·10 -3 · M v 0.80 [18] .
Elemental analysis for carbon, hydrogen, nitrogen and sulfur was used for estimation of the composition of the copolymers. 13 C NMR spectra of copolymers were taken on a Bruker MSL 300 spectrometer operating at 75.5 MHz and 300 K in D 2 O, using tetramethylsilane as a reference.
Clottability assay
The anticoagulant activity of the (co)polymers was evaluated from the values of prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT) and reptilase time (RT) according to standard methods described in ref. [19] . A coagulation analyser STA Compact-Stago (France) was used. Solutions of the (co)polymers in saline were added into human pool plasma in order to prepare series of plasma samples containing the (co)polymers with known concentrations. The time for clot formation was determined after mixing the plasma with the corresponding reagent (STA Neoplastin ® Plus, STA Thrombin, STA APTT LT, STA APTT Kaolin or STA Reptilase). The concentration of the (co)polymers was in the range from 16 µg/ml to 3 mg/ml in the total volume. In each case a control blank assay (without added (co)polymers) was performed. Heparin was used as a reference.
